BNTX vs. JAZZ: BioNTech vs. Jazz Pharmaceuticals Stock Comparison

Company Profile

BioNTech (BNTX) and Jazz Pharmaceuticals (JAZZ) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BNTX is classified in Biotechnology while JAZZ is classified in Pharmaceuticals.

Jazz Pharmaceuticals (JAZZ) trades as ordinary local shares, while BioNTech (BNTX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

BioNTech (BNTX) has an aggressive beta of 1.30, indicating higher sensitivity to broad-market moves, while Jazz Pharmaceuticals (JAZZ) is defensive at 0.33 and tends to be less market-sensitive — they sit on opposite ends of the beta spectrum.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

BioNTech (BNTX) reports a negative ROE of -8.14%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 5.05%, ranking against industry peers normally.

BioNTech (BNTX) reports a negative net margin of -60.87%, usually indicating a net loss over the period. Meanwhile Jazz Pharmaceuticals (JAZZ) reports 4.37%, ranking against industry peers normally.

Both BioNTech (BNTX) at 30.28% and Jazz Pharmaceuticals (JAZZ) at 30.17% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

Profitability Metrics

Growth

Both BioNTech (BNTX) at 4.32% and Jazz Pharmaceuticals (JAZZ) at 4.88% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Only one side can be read here: Jazz Pharmaceuticals (JAZZ) reports EPS growth of -167.51%, ranked against its industry; BioNTech (BNTX) has no EPS growth figure this period.

Growth Metrics

Financial Strength

BioNTech (BNTX) at 8.55 keeps current ratio within its industry’s typical mid-range, while Jazz Pharmaceuticals (JAZZ) at 1.82 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for JAZZ.

BioNTech (BNTX) at 0.02 keeps leverage in the lower quartile, while Jazz Pharmaceuticals (JAZZ) at 1.35 sits in the higher-leverage quartile.

Financial Strength Metrics

Dividends

Neither BioNTech (BNTX) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither BioNTech (BNTX) nor Jazz Pharmaceuticals (JAZZ) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Jazz Pharmaceuticals (JAZZ) trades at 69.46 times trailing earnings, ranked against its peers, while BioNTech (BNTX) has no P/E ratio this period.

On P/S ratio, both BioNTech (BNTX) at 8.96 and Jazz Pharmaceuticals (JAZZ) at 3.19 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BioNTech (BNTX) at 1.09 sits in the lower P/B ratio quartile against book while Jazz Pharmaceuticals (JAZZ) at 3.59 is valued near its industry’s middle — BNTX is cheaper on assets, though weigh it against ROE and asset quality.

Valuation Metrics